Summary:

• Visudyne's supply capacity was restored in Q1/2022, but not with the full extent required. Therefore, although deliveries are consistent available quantities will be limited until the end of 2023.
• CHEPLAPHARM is asking healthcare professionals to take this into account when planning and prioritizing treatments.
• CHEPLAPHARM will ensure a fair allocation and prioritize supply of Visudyne to patients in the member states that are most affected.